Multifunctional Nanoprobe for Early Appraisal of Immunotherapeutic Efficacy
用于免疫治疗功效早期评估的多功能纳米探针
基本信息
- 批准号:10372160
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesBindingBloodC57BL/6 MouseCD8-Positive T-LymphocytesCancer ModelCell LineCell physiologyCellsClinical ManagementComplexDecision MakingDetectionEarly DiagnosisEconomic BurdenElementsFinancial HardshipFluoresceinFluorescenceFluoroimmunoassayGoalsGranzymeHumanImaging technologyImmuneImmune checkpoint inhibitorImmunotherapeutic agentImmunotherapyIn VitroIndustryInfiltrationInsuranceLeadLinkMalignant NeoplasmsMeasuresMelanoma CellMetastatic MelanomaMethodsMindModalityMonitorMusNanotechnologyNeoplasm MetastasisOperative Surgical ProceduresPatientsPeptidesPharmaceutical PreparationsPlasmaPolyethylene GlycolsPositron-Emission TomographyRadiation therapyRelapseReporterReportingResearchSavingsSerumSideSignal TransductionT-Cell ActivationT-LymphocyteTechnologyTestingTherapeuticTherapeutic AgentsTimeTreatment EfficacyTumor VolumeUrineValidationanti-PD1 antibodiesantibody inhibitoranticancer researchbasecancer cellcancer immunotherapycancer therapychemical conjugatechemotherapyclinical decision-makingcostcytotoxicdesigneffector T cellfluorophoreimaging modalityimprovedin vivoin vivo evaluationinnovationmelanomamouse modelnanoGoldnanoparticlenanoprobeneoplastic cellnovelpatient responseplasmonicspre-clinicalpreclinical studypredictive markerresponseside effecttheranosticstherapy outcometumortumor growth
项目摘要
Project Summary
Despite advances in imaging technologies, it takes weeks (typically 12-14 weeks) to accurately assess the
efficacy of immunotherapy treatment. This time lag is highly undesirable for patients who are ultimately non-
responsive or relapse, as they are subject to onerous side effects and are delayed in alternate treatments. To
expedite immunotherapy related cancer research and harness the potential of immunotherapy, a technology
capable of early assessment of immunotherapy efficacy is critically important. The goal of the proposed effort
is to design, synthesize and validate a multifunctional nanoprobe for (i) efficiently administering
immunotherapy; and (ii) early detection of the cytotoxic potential of the intra-tumor T cells. With this in mind,
the following Specific Aims are proposed: Specific Aim 1: Design and synthesize a multifunctional nanoprobe
comprised of an immune checkpoint inhibitor antibody as a targeting immunotherapeutic agent and a
fluorophore-substrate complex as a predictive biomarker; and Specific Aim 2: In vivo validation of the
multifunctional nanoprobe’s immunotherapeutic potential, and its ability to rapidly monitor the response to
immunotherapy. We will utilize gold nanoparticles as a carrier for delivering anti-PD-1 antibody
(immunotherapeutic agent) and a specific cleavable substrate for granzyme B with a fluorescent reporter
element to T cells. An anti-PD-1 antibody will be chemically conjugated to the nanoparticle using a
polyethylene glycol (PEG) linker. The reporter, a fluorescein-tagged specific granzyme B substrate, will also be
conjugated to the carrier nanoparticle using another PEG linker. The interaction between activated T cells and
cancer cells should lead to localized granzyme B secretion and cleavage of the substrate, releasing
fluorescein. Plasmonic-fluor enabled competitive fluoroimmunoassay will be used for the detection of the
released reporter (fluorescein) in plasma and subsequently urine. The size of the nanoparticle will be chosen to
exploit the enhanced permeation and retention effect for improved infiltration typically seen in tumors.
Following ex vivo optimization of the activatable nanoprobe design, we will test the ability to monitor the
immuno-theranostic efficacy in vivo. An established melanoma cancer model, developed in C57BL/6 mice
using B16-F10 melanoma cells, will be utilized for this purpose although this strategy is cancer agnostic. To
investigate the therapeutic efficacy and reporting ability of the nanoprobes, tumor volume and survival will be
measured, and the results correlated with those from the serum and urine analysis for fluorescein for validation
of the therapeutic efficacy. Clearly, this is a pre-clinical study with translational implications to eventual human
studies. The overall goal is to assess the efficacy of immunotherapy treatment in patients at an early time
sparing patients the side effects of the therapy and the financial burden (to the insurance industry and/or
patient) of continued but non-durable treatment. This strategy is applicable to any therapeutic option employing
immunotherapy alone or immunotherapy in combination with conventional chemotherapy
项目摘要
尽管成像技术取得了进步,但准确评估患者的病情需要数周(通常为12-14周)。
免疫治疗的疗效。这种时间滞后对于最终非-
这些药物可能会有反应或复发,因为它们会产生繁重的副作用,并且在替代治疗中会延迟。到
加快与免疫疗法相关的癌症研究,并利用免疫疗法的潜力,
能够早期评估免疫疗法的疗效是至关重要的。拟议努力的目标是
设计、合成和验证多功能纳米探针,用于(i)有效地施用
免疫疗法;和(ii)肿瘤内T细胞的细胞毒性潜力的早期检测。考虑到这一点,
具体目标1:设计合成多功能纳米探针
包括作为靶向免疫抑制剂的免疫检查点抑制剂抗体和
荧光团-底物复合物作为预测性生物标志物;和具体目标2:
多功能纳米探针的免疫潜力,以及其快速监测对
免疫疗法。我们将利用金纳米颗粒作为载体来递送抗PD-1抗体
(免疫抑制剂)和颗粒酶B的特异性可裂解底物与荧光报告分子
元素到T细胞。抗PD-1抗体将使用免疫印迹法与纳米颗粒化学缀合。
聚乙二醇(PEG)接头。报告者,一种荧光素标记的特异性颗粒酶B底物,也将被
使用另一个PEG连接体将所述载体纳米颗粒偶联到载体纳米颗粒。活化的T细胞与
癌细胞应该导致颗粒酶B的局部分泌和底物的裂解,释放
荧光素等离子体荧光激活的竞争性荧光免疫测定将用于检测
在血浆和随后的尿液中释放报告物(荧光素)。纳米颗粒的尺寸将被选择为
利用增强的渗透和保留作用来改善通常在肿瘤中看到的浸润。
在可活化纳米探针设计的离体优化之后,我们将测试监测纳米探针的能力。
体内免疫治疗诊断功效。在C57 BL/6小鼠中建立的黑色素瘤癌症模型
使用B16-F10黑色素瘤细胞,将用于该目的,尽管该策略是癌症不可知的。到
研究纳米探针的治疗效果和报告能力,肿瘤体积和存活率将是
测量,并将结果与血清和尿液荧光素分析结果进行相关性验证
的治疗效果。显然,这是一项临床前研究,具有最终人类的转化意义。
问题研究总体目标是在早期评估患者免疫治疗的疗效
使患者免于治疗的副作用和经济负担(对保险业和/或
患者持续但不持久的治疗。该策略适用于任何采用
单独免疫治疗或免疫治疗与常规化疗联合
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEREMIAH J MORRISSEY其他文献
JEREMIAH J MORRISSEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEREMIAH J MORRISSEY', 18)}}的其他基金
Multifunctional Nanoprobe for Early Appraisal of Immunotherapeutic Efficacy
用于免疫治疗功效早期评估的多功能纳米探针
- 批准号:
10218900 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
METAL-ORGANIC FRAMEWORK AS PROTECTIVE COATING FOR CANCER BIOSPECIMEN PRESERVATION
金属有机框架作为癌症生物样本保存的保护涂层
- 批准号:
9926832 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
The Role of Bone Morphogenetic Protein-7 in Renal Endothelial Cell Biology
骨形态发生蛋白 7 在肾内皮细胞生物学中的作用
- 批准号:
7255158 - 财政年份:2007
- 资助金额:
$ 19.69万 - 项目类别:
The Role of Bone Morphogenetic Protein-7 in Renal Endothelial Cell Biology
骨形态发生蛋白 7 在肾内皮细胞生物学中的作用
- 批准号:
7386712 - 财政年份:2007
- 资助金额:
$ 19.69万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Understanding the role of malaria red blood cell binding proteins in invasion and host specificity
了解疟疾红细胞结合蛋白在侵袭和宿主特异性中的作用
- 批准号:
2723209 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Studentship
Focused ultrasound-mediated disruption of blood plasma protein binding with pharmacological molecules
聚焦超声介导破坏血浆蛋白与药理学分子的结合
- 批准号:
10046533 - 财政年份:2020
- 资助金额:
$ 19.69万 - 项目类别:
Contributions of Endothelial RNA-binding Protein Dysregulation to Blood Brain Barrier Defects and Neurodegenerative Disease
内皮 RNA 结合蛋白失调对血脑屏障缺陷和神经退行性疾病的影响
- 批准号:
10037854 - 财政年份:2020
- 资助金额:
$ 19.69万 - 项目类别:
Relationship between blood fatty acid-binding protein 4 and lipid metabolism induced by exercise
血脂肪酸结合蛋白4与运动诱导脂代谢的关系
- 批准号:
18K10838 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding and modelling platelet flow and binding in blood
了解血液中的血小板流动和结合并对其进行建模
- 批准号:
LP160100786 - 财政年份:2016
- 资助金额:
$ 19.69万 - 项目类别:
Linkage Projects
Neutralizing the human Norovirus Histo-Blood Group Antigen Binding Pocket
中和人诺如病毒组织血型抗原结合袋
- 批准号:
286792586 - 财政年份:2016
- 资助金额:
$ 19.69万 - 项目类别:
Research Units
Study of brain-type fatty acid binding protein as a biomarker of psychiatric disorder for application to blood test
脑型脂肪酸结合蛋白作为精神疾病生物标志物应用于血液检测的研究
- 批准号:
16K19189 - 财政年份:2016
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of the high blood pressure medical treatment by angiotensin receptor binding molecule
血管紧张素受体结合分子治疗高血压的研究进展
- 批准号:
24790950 - 财政年份:2012
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Imaging study on receptor binding, cerebral blood flow and metabolism in diabates mouse brain
糖尿病小鼠脑受体结合、脑血流及代谢的影像学研究
- 批准号:
24591759 - 财政年份:2012
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of role of fatty acid-binding protein in vascular endothelial function and blood pressure control
阐明脂肪酸结合蛋白在血管内皮功能和血压控制中的作用
- 批准号:
23591106 - 财政年份:2011
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)